- Home
- ALLR vs DRMA Comparison
ALLR vs DRMA Comparison
Compare ALLR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- DRMA
- Stock Information
- Founded
- ALLR 2004
- DRMA 2014
- Country
- ALLR United States
- DRMA United States
- Employees
- ALLR N/A
- DRMA N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- DRMA Health Care
- Exchange
- ALLR Nasdaq
- DRMA Nasdaq
- Market Cap
- ALLR 13.3M
- DRMA 4.5M
- IPO Year
- ALLR N/A
- DRMA 2021
- Fundamental
- Price
- ALLR $1.05
- DRMA $0.62
- Analyst Decision
- ALLR
- DRMA Strong Buy
- Analyst Count
- ALLR 0
- DRMA 1
- Target Price
- ALLR N/A
- DRMA $3.00
- AVG Volume (30 Days)
- ALLR 448.4K
- DRMA 81.1K
- Earning Date
- ALLR 08-04-2025
- DRMA 08-06-2025
- Dividend Yield
- ALLR N/A
- DRMA N/A
- EPS Growth
- ALLR N/A
- DRMA N/A
- EPS
- ALLR N/A
- DRMA N/A
- Revenue
- ALLR N/A
- DRMA N/A
- Revenue This Year
- ALLR N/A
- DRMA N/A
- Revenue Next Year
- ALLR N/A
- DRMA N/A
- P/E Ratio
- ALLR N/A
- DRMA N/A
- Revenue Growth
- ALLR N/A
- DRMA N/A
- 52 Week Low
- ALLR $0.61
- DRMA $0.64
- 52 Week High
- ALLR $10.59
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- ALLR 51.07
- DRMA 30.10
- Support Level
- ALLR $0.80
- DRMA $0.65
- Resistance Level
- ALLR $0.98
- DRMA $0.73
- Average True Range (ATR)
- ALLR 0.06
- DRMA 0.05
- MACD
- ALLR 0.01
- DRMA -0.01
- Stochastic Oscillator
- ALLR 69.64
- DRMA 0.00
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.